Skip to main content
Top
Published in: International Journal of Clinical Oncology 3/2016

01-06-2016 | Original Article

Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers

Authors: Takeo Minaguchi, Toyomi Satoh, Koji Matsumoto, Manabu Sakurai, Hiroyuki Ochi, Mamiko Onuki, Akinori Oki, Hiroyuki Yoshikawa

Published in: International Journal of Clinical Oncology | Issue 3/2016

Login to get access

Abstract

Background

The selection criteria for secondary cytoreductive surgery (SCS) in recurrent ovarian cancer are yet to be defined. The aim of this study was to propose the selection criteria through identifying predictive factors for successful SCS.

Methods

All patients who underwent SCS for recurrent epithelial ovarian, tubal, and peritoneal cancers between 1982 and 2012 at our institution were identified through our database. Potential prognostic factors were evaluated in univariate and multivariate analyses. Survival after SCS was examined by the grouping model based on the number of prognostic factors.

Results

We performed SCS in 80 consecutive patients, 48 (60 %) of whom achieved complete resection. Complete/incomplete resection significantly influenced survival (median 65 vs. 26 months; p = 0.0005). Among favorable prognostic factors determined before SCS, treatment-free interval >12 months, absent distant metastasis, solitary disease, and performance status 0 were independently associated with better survival (p = 0.0009, 0.00003, 0.0004, and 0.015, respectively). Patients with 3–4 of those factors had better survival than those with 2 or 0–1 factors (median 79, 26, and 19 months; p < 0.00001 and <0.0000000001, respectively). Complete resection of visible tumors was achieved in 79 % of patients with 3–4 factors, in 40 % of those with 2 factors, and in 33 % of those with 0–1 factor. Importantly, even when tumor removal was incomplete at SCS, median survival of patients with 3–4 factors was still quite favorable (83 vs. 67.5 months for complete/incomplete resection, respectively), while those of patients with 2 factors (41 vs. 25 months) and 0–1 factor (19 vs. 19 months) were not.

Conclusion

We strongly recommend SCS for patients with 3–4 of the above favorable factors at recurrence. As for patients with 2 factors, SCS may be considered if complete resection is expected to be achieved. Prospective studies are warranted to validate our proposal.
Literature
1.
go back to reference Stuart GC, Kitchener H, Bacon M et al (2011) 2010 Gynecologic Cancer Inter Group (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth ovarian cancer consensus conference. Int J Gynecol Cancer 21:750–755CrossRefPubMed Stuart GC, Kitchener H, Bacon M et al (2011) 2010 Gynecologic Cancer Inter Group (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth ovarian cancer consensus conference. Int J Gynecol Cancer 21:750–755CrossRefPubMed
2.
go back to reference Onda T, Yoshikawa H, Yasugi T et al (2005) Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer 92:1026–1032CrossRefPubMedPubMedCentral Onda T, Yoshikawa H, Yasugi T et al (2005) Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer 92:1026–1032CrossRefPubMedPubMedCentral
3.
go back to reference Parmar MK, Ledermann JA, Colombo N et al (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099–2106CrossRefPubMed Parmar MK, Ledermann JA, Colombo N et al (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099–2106CrossRefPubMed
4.
go back to reference Wagner U, Marth C, Largillier R et al (2012) Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer 107:588–591CrossRefPubMedPubMedCentral Wagner U, Marth C, Largillier R et al (2012) Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer 107:588–591CrossRefPubMedPubMedCentral
5.
go back to reference Aghajanian C, Blank SV, Goff BA et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039–2045CrossRefPubMedPubMedCentral Aghajanian C, Blank SV, Goff BA et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039–2045CrossRefPubMedPubMedCentral
6.
go back to reference Harter P, Heitz F, du Bois A et al (2012) Surgery for relapsed ovarian cancer: when should it be offered? Curr Oncol Rep. 14:539–543CrossRefPubMed Harter P, Heitz F, du Bois A et al (2012) Surgery for relapsed ovarian cancer: when should it be offered? Curr Oncol Rep. 14:539–543CrossRefPubMed
7.
go back to reference Harter P, du Bois A, Hahmann M et al (2006) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13:1702–1710CrossRefPubMed Harter P, du Bois A, Hahmann M et al (2006) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13:1702–1710CrossRefPubMed
8.
go back to reference Sehouli J, Richter R, Braicu EI et al (2010) Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? a systematic analysis of 240 consecutive patients. J Surg Oncol 102:656–662CrossRefPubMed Sehouli J, Richter R, Braicu EI et al (2010) Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? a systematic analysis of 240 consecutive patients. J Surg Oncol 102:656–662CrossRefPubMed
9.
go back to reference Oksefjell H, Sandstad B, Trope C (2009) The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Ann Oncol 20:286–293CrossRefPubMed Oksefjell H, Sandstad B, Trope C (2009) The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Ann Oncol 20:286–293CrossRefPubMed
10.
go back to reference Tian WJ, Jiang R, Cheng X et al (2010) Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 0.1–1 cm after secondary cytoreduction. J Surg Oncol 101:244–250PubMed Tian WJ, Jiang R, Cheng X et al (2010) Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 0.1–1 cm after secondary cytoreduction. J Surg Oncol 101:244–250PubMed
11.
go back to reference Zang RY, Li ZT, Tang J et al (2004) Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 100:1152–1161CrossRefPubMed Zang RY, Li ZT, Tang J et al (2004) Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 100:1152–1161CrossRefPubMed
12.
go back to reference Zang RY, Harter P, Chi DS et al (2011) Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer 105:890–896CrossRefPubMedPubMedCentral Zang RY, Harter P, Chi DS et al (2011) Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer 105:890–896CrossRefPubMedPubMedCentral
13.
go back to reference Eisenkop SM, Friedman RL, Spirtos NM (2000) The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88:144–153CrossRefPubMed Eisenkop SM, Friedman RL, Spirtos NM (2000) The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88:144–153CrossRefPubMed
14.
go back to reference Chi DS, McCaughty K, Diaz JP et al (2006) Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106:1933–1939CrossRefPubMed Chi DS, McCaughty K, Diaz JP et al (2006) Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106:1933–1939CrossRefPubMed
15.
go back to reference Harter P, Sehouli J, Reuss A et al (2011) Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 21:289–295CrossRefPubMed Harter P, Sehouli J, Reuss A et al (2011) Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 21:289–295CrossRefPubMed
Metadata
Title
Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers
Authors
Takeo Minaguchi
Toyomi Satoh
Koji Matsumoto
Manabu Sakurai
Hiroyuki Ochi
Mamiko Onuki
Akinori Oki
Hiroyuki Yoshikawa
Publication date
01-06-2016
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 3/2016
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-015-0910-8

Other articles of this Issue 3/2016

International Journal of Clinical Oncology 3/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine